Source: Annual Congress 2007 - New treatments for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bateman, H. Nelson, R. Beasley, J. Bousquet, S. Yancey, K. Kral, L. Sutton, P. Dorinsky (Wellington, New Zealand; Denver, CO, RTP, NC, United States Of America; Cape Town, South Africa; Montpellier, France). Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis. Eur Respir J 2007; 30: Suppl. 51, 2128

Member's Comments

No comment yet.

Related content which might interest you: Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Effect of allergic rhinitis on asthma-related hospitalization, GP visit and drug cost among adult asthmatic patients in the UK Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002 Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002 Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD Source: Eur Respir J 2010; 36: 494-502 Year: 2010 AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Adherence to inhaled corticosteroids before and after an asthma-related hospitalisation: distinct trajectories Source: International Congress 2018 – Epidemiology of asthma, COPD and factors that associate with lung function Year: 2018 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005 Effect of β2-agonists on severe asthma exacerbation and asthma-related hospitalization Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Reduction in asthma-related costs following treatment with montelukast (PRAACTICAL study) Source: Eur Respir J 2005; 26: Suppl. 49, 577s Year: 2005 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Risk of asthma-related emergency department (ED)/hospitalization events in patients with consistent, variable or intermittent inhaled corticosteroids (ICS) Source: Eur Respir J 2005; 26: Suppl. 49, 220s Year: 2005 The effect of tiotropium in COPD complicated with asthma Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016